Assertio Holdings Inc
NASDAQ:ASRT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Assertio Holdings Inc
Cash & Cash Equivalents
Assertio Holdings Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Assertio Holdings Inc
NASDAQ:ASRT
|
Cash & Cash Equivalents
$10.2m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-20%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash & Cash Equivalents
$9.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
16%
|
CAGR 10-Years
-4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash & Cash Equivalents
$10.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
16%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash & Cash Equivalents
$1.1B
|
CAGR 3-Years
40%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-11%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash & Cash Equivalents
$14.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
13%
|
CAGR 10-Years
6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash & Cash Equivalents
$7.3B
|
CAGR 3-Years
52%
|
CAGR 5-Years
15%
|
CAGR 10-Years
7%
|
|
Assertio Holdings Inc
Glance View
Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.
See Also
What is Assertio Holdings Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
10.2m
USD
Based on the financial report for Dec 31, 2025, Assertio Holdings Inc's Cash & Cash Equivalents amounts to 10.2m USD.
What is Assertio Holdings Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-20%
Over the last year, the Cash & Cash Equivalents growth was -80%. The average annual Cash & Cash Equivalents growth rates for Assertio Holdings Inc have been -46% over the past three years , -13% over the past five years , and -20% over the past ten years .
